DRD2 and neoplasm: Further, at low pharmacological doses, DA delays tumor angiogenesis by inhibiting VEGFR-2 phosphorylation in endothelial cells that express D2R, as reported in rat malignant gastric tumors (adenocarcinoma type) and xenotransplanted human gastric cancers in mice.